Neurocrine biosciences to present data from its neurology portfolio at the american academy of neurology's 73rd 2021 virtual meeting

San diego, april 8, 2021 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present data from its movement disorders and epilepsy programs at the american academy of neurology's (aan) 73rd annual meeting being held virtually from april 17–22, 2021. key highlights include: analysis from the kinect 4 phase iii open-label study that demonstrated the effect of ingrezza® (valbenazine) capsules on the overall severity of abnormal movements in adult patients living with tardive dyskinesia based on item 8 of the abnormal involuntary movement scale (aims) phase iii post-hoc sub-group data analysis that showed long-term use (one-year duration) of ongentys® (opicapone) capsules in patients with parkinson's disease with motor fluctuations reduced "on" time with troublesome dyskinesia and increased "on" time without troublesome dyskinesia new real-world data from empathy, a retrospective medical chart review, highlight the need to simplify treatment regimens for patients with parkinson's disease to manage motor fluctuations results of an online caregiver survey include data on the relationship between genetic variants and disease characteristics in patients with scn8a developmental epileptic encephalopathy (scn8a-dee) and scn8a-related epilepsy data from the enroll-hd registry, a worldwide observational study, showed that the majority of patients with manifest huntington disease have chorea, yet the majority of those with chorea were not prescribed medication to treat the condition.
NBIX Ratings Summary
NBIX Quant Ranking